| Name | Title | Contact Details |
|---|
Orthofix Medical Inc. began in a small farmhouse in Verona Italy in 1980 when orthopedic researcher Giovanni De Bastiani recognized the bone`s natural repair capability, a concept he called “dynamization.” With that in mind, he created the first external fixation device. Today, Orthofix has grown to more than 1,200 employees with locations in the U.S., Italy, Germany, France, the U.K., Brazil, and Australia. Our products help patients in more than 70 countries around the world. The Company`s mission is to deliver innovative, quality-driven solutions as we partner with health care professionals to improve patient mobility. Headquartered in Lewisville, Texas, the company has two strategic business units: Spine and Orthopedics. Orthofix products are widely distributed via the company`s sales representatives and distributors. In addition, Orthofix is collaborating on research and development activities with leading clinical organizations such as MTF Biologics, the Orthopedic Research and Education Foundation, and the Texas Scottish Rite Hospital for Children. Orthofix makes a difference in the lives of others by providing our surgeon customers with innovative medical devices to meet the needs of their patients. Every day we are optimizing our operations, improving efficiencies, and examining our systems to provide the best support possible to our representatives, surgeons and patients.
Carol Cole Company is a Encinitas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
LIFESPAN is a multi-disciplinary, integrated team of professionals who serve individuals in a seven county region. LIFESPAN, a subsidiary of Battle Creek Health System, is an organization comprised of uniquely talented people with a common vision: To
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.
Remington Products is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.